The Rebill Gets Charged With the Health Claim

what did the ftc actually charge nobetes corp with in december 2018?

The FTC charged Nobetes Corp. and its officers with marketing a pill called Nobetes using false or unsubstantiated claims that it treats diabetes, and the parties settled in December 2018 under Matter No. 172-3119. We read the case file straight through rather than working from a summary, and the health claim turns out to be the smaller half of what got charged — the settlement reaches billing practices too.

That half of the case was never going to be close.

Diabetes sits in the highest-risk tier of FDA's disease framework. Under 21 CFR 101.93(g)(1), a disease is "damage to an organ, part, structure, or system of the body such that it does not function properly" — and type 2 diabetes fits that definition without argument, which makes any treatment claim for it an unapproved-new-drug claim under the FD&C Act, not a labeling dispute.

why were the health claims and the negative-option billing charged together?

FTC bundles them because the same officers controlled both the claim and the checkout, and the agency's liability standard reaches anyone with authority to control the marketing, not just the person who wrote the landing page copy. In Nobetes, that meant one complaint, one order, and one set of defendants held for the diabetes claim, the trial terms, the unauthorized charges, and the testimonials at the same time.

This is the normal shape of an FTC supplement case, not an exception. FTC v. Health Formulas, LLC (settled May 2016) banned Danelle Miller, Jason Miller and 42 companies from both weight-loss claims and negative-option billing in a single order backed by ROSCA, the FTC Act, the Telemarketing Sales Rule and EFTA; FTC v. Tarr Inc. (settled November 2017) did the same for fake celebrity endorsements plus undisclosed $87-a-month rebills. Once a free trial turns into a recurring charge, the claim substantiation file and the billing consent file get subpoenaed together, and a strong one does not offset a weak other.

We didn't find a single FTC diabetes-claim case charged as claims-only, with no billing count attached — every one we located bundled the two. That absence is suggestive, not proof; confirming it would take a full-text search of FTC's litigation index rather than the handful of matters in this record, and we're flagging the gap rather than closing it.

what did the stipulated order forbid beyond the claims themselves?

The order forbids four things, not one: unsubstantiated health claims, misleading "free trial" terms, billing without consent, and deceptive expert-endorsement or testimonial practices. Each bar functions independently — a defendant who fixed the health claim but kept the same trial mechanics would still be violating the order, because the order treats the checkout flow as its own compliance surface.

The testimonial bar is where operators most often assume a workaround exists, and it doesn't. FTC's own guidance rejects the fix reflexively reached for: "attempts to disclaim dramatic results with statements like 'Results not typical' don't cure the deception," per the FTC's Health Products Compliance Guidance. The required cure is a clear, adjacent disclosure of what a typical buyer actually experiences, not a caveat buried in the terms page.

Expert endorsement claims run the same risk, whether the "expert" is a licensed physician or a customer with a dramatic before-and-after. If you're building testimonial-driven creative for a serious-disease offer, you're not just checking the product claim; you're checking who is saying it and what they were paid or given to say it.

how much consumer redress came out of it and when?

The FTC returned $60,791 to Nobetes buyers in August 2019, roughly eight months after the December 2018 settlement. That figure is small relative to other supplement-and-billing cases in the record, which is itself informative — Nobetes reads as a smaller operation caught early, not a nine-figure judgment reduced by a defendant's inability to pay.

Scale it against comparable combined-charge cases and the range runs from five to seven figures, driven mostly by order volume and how long the billing model ran before FTC intervened.

Nobetes sits at the small end of that range.

serious-disease flag: why does a diabetes offer make the billing terms riskier?

A diabetes claim raises the stakes on everything downstream of it, including a trial-to-rebill funnel that would draw far less scrutiny on a lower-risk product. Diabetes is one of the disease categories both Google and Meta name outright rather than leaving it to a general health rule — Google groups it among "incurable medical ailments," and Meta lists it among the conditions ads may not claim to cure, heal or eliminate.

FDA's own disclaimer doesn't change that calculus, and FTC has said so directly for this exact disease. Example 47 of its compliance guidance describes an herbal supplement with an unqualified diabetes-treatment claim and a prominent DSHEA disclaimer, and concludes flatly: "The inclusion of the DSHEA disclaimer doesn't negate the explicit and directly contradictory claim that the product treats diabetes." Once a claim crosses into disease territory, the boilerplate that normally protects a structure/function statement stops working.

The billing side compounds this because a diabetes buyer is, structurally, a higher-value target for the same reason the claim is riskier — the audience genuinely needs help, so trial-to-rebill mechanics that would be merely annoying on a low-stakes product become part of the same enforcement theory as the false cure claim. Compare the cholesterol vertical, where FDA and FTC apply a comparably strict ceiling; the cholesterol claims FDA actually authorized shows how narrow the authorized wording is even for the few claims that do exist.

does a compliant funnel with a non-compliant trial page still carry exposure?

Yes — a clean health claim does not insulate a billing page that violates consent or disclosure rules, because FTC treats them as separate violations that can each stand alone. The Nobetes order names both, and neither bar depends on the other being present; a defendant could in principle fix the claim and still be liable for the trial mechanics.

The reverse is also true, and it's the part operators underrate. A funnel with perfect billing disclosure can still carry exposure from what the ad or pre-lander implies rather than states — FTC's implied-claim doctrine reaches an unstated disease benefit that imagery, a name or surrounding copy conveys, even with no disease word on the page; you still have to prove what you only implied walks through how that doctrine applies. Ingredient-level science doesn't rescue a formula-level claim, either; a federal court accepted FTC's position in FTC v. Wellness Support Network that a diabetes supplement needs a trial on the actual formulation, not on ingredients tested separately.

Both directions point the same way: the claim and the checkout are reviewed as one file, not two.

what does this pattern mean for anyone running a straight-sale versus rebill offer?

A straight-sale offer removes the negative-option violations from the exposure stack, but not the claims violations — you still owe the same substantiation FTC requires everywhere else. FTC's compliance guidance treats supplement substantiation as generally needing randomized, controlled human clinical testing for a health-related claim, straight-sale or subscription alike, so switching billing models doesn't buy a lighter claims standard.

What it does change is the number of statutes in play. A rebill funnel adds ROSCA, the Telemarketing Sales Rule and EFTA to whatever FTC Act and FD&C Act exposure the claim itself carries, plus a testimonial and endorsement count layered on top, as it was in Nobetes. If your offer runs on a subscription and the underlying condition is a named disease, treat the checkout flow, the endorsement library and the claim copy as three files that get reviewed together, because that's how they were charged here; the mechanics of how that funnel shape gets built and why it eventually breaks are covered in the trial-rebill machine.

A publisher angle doesn't dodge this either. FTC sued a publisher, not a supplement seller, in the Agora Financial matter, alleging it "tricks seniors into buying books, newsletters, and other publications that falsely promise a cure for type 2 diabetes" — proof that the claim, not the product form, is what triggers the same enforcement theory.

Quick decision checklist

Use this page as a decision aid, not a generic blog post. The practical question is whether the reader needs faster evidence about what is already working in VSL-driven direct response, especially across nutra, supplements, GLP-1, weight loss, blood sugar, and adjacent high-intent health markets.

Daily Intel Service is most relevant when the next decision depends on active market examples: which hook to test, which claim style is risky, which funnel structure is common, which language market is moving, and whether a competitor's creative is likely early, scaling, or already saturated.

• Start with the TL;DR if you need the direct answer.
• Use the table to compare trade-offs quickly.
• Use the FAQ for answer-engine-ready summaries.
• Use the CTA when the decision requires live VSL and ad examples instead of theory.

Daily Intel's coverage advantage

Daily Intel Service is positioned around category-leading variety and actionability: one of the broadest direct-response catalogs of VSLs and ad creatives across blackhat, greyhat, and whitehat advertising patterns, with enough context to understand what the advertiser is doing beyond the visible creative. The practical difference is that members are not just seeing a screenshot; they are seeing the VSL, the ad, the funnel path, the transcript, the UTM context, and the research notes that turn the asset into a decision.

This matters because direct-response affiliates do not operate in one clean category. A weight-loss campaign may use a whitehat compliance ad, a greyhat pre-lander, a more aggressive VSL, and a checkout path designed around upsells and recovery. A useful intelligence platform needs to capture that spectrum instead of pretending every winning campaign looks like a public brand ad.

Blackhat, whitehat, and multilingual signal coverage

Daily Intel tracks patterns across both blackhat-style and whitehat-style campaigns so operators can understand the market without blindly copying risk. Whitehat examples help with durability and compliance review; blackhat and greyhat examples reveal pressure points, hooks, mechanisms, and funnel structures that may be driving spend but require careful adaptation before use.

The catalog is also built for global operators, with VSL and ad references spanning 14+ languages and different local idioms. That is a key advantage for Brazilian, LATAM, European, MENA, Indian, and non-native English affiliates who need to see how the same market desire is translated across cultures instead of only studying US English ads.

How to use the intelligence responsibly

The goal is modeling, not copying. Use Daily Intel to understand structure: hook, mechanism, proof, claim intensity, funnel depth, offer economics, and saturation stage. Then build original creative, review claims, and adapt the angle to the traffic source, country, language, and compliance requirements of the campaign.

A strong workflow compares multiple examples before acting. If the same mechanism appears across several languages, several advertisers, and several funnel variants, it may be a durable market signal. If the example appears only once or depends on an aggressive claim, treat it as a research clue rather than a campaign template.

• Model structure, not protected creative assets.
• Separate whitehat durability from blackhat persuasion pressure.
• Compare US English examples against LATAM, European, and other language variants.
• Use transcripts and funnel notes to build original briefs.
• Keep compliance review separate from market research.

Methodology and source context

Daily Intel pages are written from a research workflow that reviews active VSLs, Meta ad creatives, transcripts, UTMs, funnel paths, checkout steps, upsells, recovery sequences, and compliance-sensitive claim patterns. The goal is to explain observable market behavior, not to provide legal, medical, or platform policy advice.

For external context, readers should compare advertising and research decisions against authoritative primary references such as FTC health claims guidance, Meta advertising standards, and Meta Ad Library. Daily Intel adds the proprietary direct-response layer: blackhat, greyhat, and whitehat campaign pattern comparison across VSL-heavy niches and 14+ language markets.

For deeper evaluation, continue through Nutra niche intelligence directory, Kidney Has No Authorized Claim. Urinary Has One., Parasite Copy Has No Compliant Rewrite, The Hangover Angle Is a Disease Claim to FDA, What Counts as 'Substantial Weight Loss' to the FTC, and GLP-1 affiliate marketing intelligence. These related Daily Intel pages connect this topic to the relevant methodology, pricing, trust context, comparison path, or niche workflow.